Physicians' Academy for Cardiovascular Education

ACS

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

No added value of monitoring platelet function after ACS

3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
##SCROLLER_ITEMS_FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

10' education - Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby

Cardiovascular Inflammation and Immunity in Atherosclerosis:

10' education - June 7, 2015 - Amsterdam
##SCROLLER_ITEMS_FULL_TITLE##

HDL mimetics: New promise in ACS?

3' education - Sep. 15, 2014 - Barcelona 2014 - Prof Kausik Ray MD
##SCROLLER_ITEMS_FULL_TITLE##

New registries on ACS/PCI: how does the real world look like

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

Latest guidelines on ACS/PCI: what are the key changes?

10' education - Sep. 2, 2014 - Barcelona, ESC - Prof. Petr Widimsky, Prague, Czech Republic
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI :Patient cases based on real world data

10' education - Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI: Patient cases based on latest guidelines

10' education - Sep. 1, 2014 - Barcelona, ESC - Professor Petr Widimský

Statin-loaded HDL nanoparticles

10' education - Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD
Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.

ACC 2019 Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.

Antithrombotic regime with NOAC but no aspirin most favorable for patients with AF and ACS/PCI

News - Mar. 17, 2019

ACC 2019 The AUGUSTUS trial showed less bleeding and fewer hospitalizations without differences in ischemic events with apixaban and no aspirin, as compared with regimens with VKA, aspirin or both.

hsCRP levels at and after ACS associated with risk of recurrent MACE and death

Literature - Mar. 12, 2019 - Mani P et al., - JAMA Cardiol. 2019

In a secondary analysis of the VISTA-16 trial, hsCRP levels measured at the time of ACS and increases of hsCRP in the 16 weeks after, were correlated with MACE, all-cause and CV death.

Retraction of meta-analysis on statin loading pre-PCI for ACS

News - Mar. 1, 2019

RETRACTION 7 Out of 13 studies included in a meta-analysis of RCTs on atorvastatin loading prior to PCI for ACS should have been excluded based on the study’s selection criteria. A corrected analysis substantively alters the results.

Evaluation of DAPT duration in post-PCI patients stratified for bleeding score and ischemic risk

Literature - Feb. 28, 2019 - Costa F et al. - JACC 2019
A retrospective analysis of RCTs suggests that when ischemic and bleeding risks are concordant, bleeding risk should inform decision-making on DAPT duration more so than ischemic risk.

A retrospective analysis of RCTs suggests that when ischemic and bleeding risks are concordant, bleeding risk should inform decision-making on DAPT duration more so than ischemic risk.

Transportation noise linked to MI mortality in adults, independently of air pollution

Literature - Feb. 26, 2019 - Héritier H et al. - Eur Heart J 2018

Noise from road traffic, railway and aircraft were associated with MI mortality in a cohort of adults, independently of air pollution, in a model that assessed individual exposure at the address and floor level.

Diet drinks associated with increased risk of CV outcomes and all-cause mortality in postmenopausal women

Literature - Feb. 25, 2019 - Mossavar-Rahmani Y et al. - Stroke 2019

Self-reported consumption of ≥2 artificially sweetened beverages per day was associated with higher risk of CV events, and all-cause mortality in postmenopausal women, as shown in an observational study.

Long-term statin adherence inversely associated with all-cause mortality in ASCVD

Literature - Feb. 19, 2019 - Rodriguez F et al. - JAMA Cardiol 2019
A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.

A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.

PCSK9 inhibitor reduces first and subsequent nonfatal CV events and death after ACS

Literature - Feb. 11, 2019 - Szarek M et al., - J Am Coll Cardiol. 2019

In a total events analysis of ODYSSEY OUTCOMES, treatment with alirocumab reduced the total burden of fatal and nonfatal CV events in a post-ACS population, as compared with placebo.

Coronary plaque characteristics and CAC score in relation to CHD risk in CAD patients

Literature - Feb. 5, 2019 - Williams MC et al. - JACC 2019

Obstructive CAD and adverse coronary plaque characteristics on CTA were associated with increased risk for CHD death or non-fatal MI, but CAC score was the only significant predictor of CHD risk in a post-hoc analysis of the SCOT-HEART trial.

Elevated cTn levels of unknown etiology can predict major adverse outcomes in suspected ACS

Literature - Jan. 31, 2019 - Eggers KM et al. - JACC 2019

A retrospective registry-based cohort study demonstrated that elevated cardiac troponin levels can predict major adverse outcomes in patients admitted with suspected ACS in whom no definite diagnosis was established.

Reduced CV events with loading dose of statin before PCI in patients with ACS

Literature - Jan. 28, 2019 - Ye Z et al. - Eur Heart J 2019

A meta-analysis of 13 randomized controlled trials showed that a loading dose of atorvastatin before PCI markedly reduced MACE in patients with ACS.